查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103001

前列腺癌診斷市場：策略性洞察與預測（2026-2035 年）

Prostate Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計攝護腺癌診斷市場將從 2026 年的 76.6 億美元成長到 2035 年的 163.2 億美元，複合年成長率為 8.8%。

前列腺癌的診斷在早期發現、風險分層、治療方案製定和疾病後續觀察管理中起著至關重要的作用。醫療專業人員越來越注重識別具有臨床意義的癌症，同時減少不必要的切片檢查和過度治療。由於前列腺癌具有高度的生物學異質性，診斷技術的創新正朝著基於高特異性生物標記的檢測和先進的影像技術方向發展，從而實現更精準的患者管理。基因組分析、液態生物檢體技術、人工智慧 (AI) 和精準醫療方法的整合正在顯著改變前列腺癌的診斷格局。

市場促進因素

精準腫瘤學的廣泛應用

精準醫療對前列腺癌的治療管理正產生日益顯著的影響。臨床醫生現在利用基因組和分子生物標記來製定治療策略、預測疾病進展，並識別最有可能從標靶治療中獲益的患者。這一趨勢正在推動對先進分子診斷解決方案的需求。

老齡人口的增加

前列腺癌的發生率老齡化顯著增加。隨著世界人口老化，醫療機構的篩檢數量不斷增加，對能夠支持早期療育的精準診斷技術的需求也日益成長。

提高風險分層準確性的需求日益成長

傳統的基於PSA的篩檢常常導致假陽性結果和不必要的切片檢查。醫療機構正擴大採用先進的風險分層技術，以幫助提高診斷特異性，並區分高度侵襲性癌症和生長緩慢的病變。

多參數磁振造影技術的應用範圍不斷擴大

多參數磁振造影已成為重要的診斷工具，因為它可以在侵入性手術前清晰地顯示前列腺病變。它的應用提高了切片檢查的靶向精度，並有助於減少不必要的手術干預。

市場限制因素

對假陽性的擔憂

PSA檢測在特異性方面仍面臨挑戰。假陽性結果可能導致不必要的切片檢查、患者焦慮以及醫療成本增加。

監管和檢驗要求

監管機構越來越要求在批准新的診斷技術之前，提供強力的臨床檢驗和臨床效用證據。這些要求可能會導致產品上市時間延長和研發成本增加。

先進診斷技術高成本

基因組檢測、分子診斷和先進影像技術通常需要大量投資，這可能會限制它們在某些醫療機構和新興市場的普及。

目錄

第1章執行摘要

  • 市場概述
  • 主要發現
  • 分析師意見
  • 策略建議

第2章：調查方法

  • 調查設計
  • 資料收集和調查方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章 前列腺癌診斷市場：概述、市場規模與預測

  • 市場定義和範圍
  • 疾病概述
  • 產業變化
  • 主要市場趨勢
  • 市場規模表現分析
  • 市場預測分析
  • 疾病負擔與未滿足的診斷需求
  • 流行病學和盛行率分析
  • 已確診患者族群的分析
  • 篩檢和檢測量分析
  • 病人歷程分析
  • 前列腺癌篩檢現狀
  • 精準腫瘤診斷概述

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 前列腺癌診斷領域的新興技術
  • 產品創新分析
  • 液態生物檢體進展
  • 分子和基因生物標記的進展
  • 多參數成像技術的創新
  • 臨床試驗分析
  • 管道分析
  • 人工智慧在前列腺癌檢測和風險分層的應用。
  • 數位病理學與診斷工作流程的整合
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：前列腺癌診斷市場：展望分析

  • 分析：按技術平台
  • 分析：依生物標記類型
  • 分析：依樣本類型
  • 分析：透過臨床應用
  • 分析：透過調查方法
  • 分析：篩檢試驗與診斷試驗的比較
  • 分析：按最終用戶

第9章：前列腺癌診斷市場：細分市場分析

  • 按產品/服務
    • 裝置
    • 試劑和耗材
    • 軟體和診斷分析解決方案
    • 診斷檢測服務
  • 透過診斷技術
    • 前列腺特異性抗原（PSA）檢測
    • 免費PSA和PSA衍生物檢測
    • 前列腺健康指數 (PHI) 測試
    • PCA3 測試
    • 基因組和分子診斷
    • 液態生物檢體
    • 多參數磁振造影（mpMRI）
    • 基於組織切片檢查的診斷
  • 透過使用
    • 篩檢和早期檢測
    • 疾病的診斷和最終診斷
    • 風險分層
    • 治療方案和伴隨診斷
    • 疾病後續觀察和復發檢測
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 癌症中心
    • 學術研究機構
    • 其他最終用戶

第10章 攝護腺癌診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章：攝護腺癌診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 中國
  • 日本
  • 韓國
  • 澳洲
  • 印度
  • 巴西
  • 沙烏地阿拉伯

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 併購、合作與聯盟
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Bio-Techne Corporation
  • OPKO Health, Inc.
  • MDxHealth SA
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Danaher Corporation
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Veracyte, Inc.
  • Genomic Health, Inc.
  • Natera, Inc.

第14章：前列腺癌診斷市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009005

The prostate cancer diagnostics market is predicted to grow from USD 7.66 billion in 2026 growing at a CAGR of 8.8% to make up USD 16.32 billion in 2035.

Prostate cancer diagnostics play a critical role in early detection, risk stratification, treatment planning, and disease monitoring. Healthcare providers are increasingly focusing on identifying clinically significant cancers while reducing unnecessary biopsies and overtreatment. As prostate cancer exhibits substantial biological heterogeneity, diagnostic innovation is shifting toward highly specific biomarker-based tests and advanced imaging modalities that enable more accurate patient management. The integration of genomic profiling, liquid biopsy technologies, artificial intelligence (AI), and precision medicine approaches is transforming the prostate cancer diagnostic landscape.

Market Drivers

Growing Adoption of Precision Oncology

Precision medicine is increasingly influencing prostate cancer management. Clinicians now rely on genomic and molecular biomarkers to guide treatment decisions, predict disease progression, and identify patients most likely to benefit from targeted therapies. This trend is increasing demand for advanced molecular diagnostic solutions.

Expanding Aging Population

The incidence of prostate cancer rises significantly with age. As global populations continue aging, healthcare systems are witnessing increasing screening volumes and growing demand for accurate diagnostic technologies capable of supporting early intervention.

Rising Demand for Improved Risk Stratification

Traditional PSA-based screening often leads to false positives and unnecessary biopsies. Healthcare providers are increasingly adopting advanced risk stratification technologies that improve diagnostic specificity and help distinguish aggressive cancers from indolent disease.

Increasing Adoption of Multiparametric MRI

Multiparametric MRI has become an important diagnostic tool because it provides superior visualization of prostate lesions before invasive procedures. Its use improves biopsy targeting and helps reduce unnecessary interventions.

Market Restraints

Concerns Regarding False Positives

PSA testing continues to face limitations related to specificity. False-positive results may lead to unnecessary biopsies, patient anxiety, and increased healthcare expenditures.

Regulatory and Validation Requirements

Regulatory authorities increasingly require strong clinical validation and evidence of clinical utility before approving new diagnostic technologies. These requirements can extend commercialization timelines and increase development costs.

High Cost of Advanced Diagnostics

Genomic testing, molecular diagnostics, and advanced imaging technologies often require significant investment, limiting accessibility in some healthcare settings and emerging markets.

Market and Technology Insights

The global prostate cancer diagnostics market can be segmented by product & service, diagnostic technology, application, end user, and geography.

By product & service, the market includes:

  • Instruments
  • Reagents & Consumables
  • Software & Diagnostic Analytics Solutions
  • Diagnostic Testing Services

Reagents and consumables account for a substantial portion of market revenue because of recurring testing demand across diagnostic laboratories and healthcare facilities.

By diagnostic technology, the market comprises:

  • Prostate-Specific Antigen (PSA) Testing
  • Free PSA and PSA Derivative Testing
  • Prostate Health Index (PHI) Testing
  • PCA3 Testing
  • Genomic and Molecular Diagnostics
  • Liquid Biopsy Testing
  • Multiparametric MRI (mpMRI)
  • Tissue Biopsy-Based Diagnostics

Genomic diagnostics, liquid biopsy technologies, and advanced imaging modalities are expected to experience significant growth as healthcare providers seek greater diagnostic accuracy and personalized treatment pathways.

By application, the market includes:

  • Screening and Early Detection
  • Disease Diagnosis and Confirmation
  • Risk Stratification
  • Treatment Selection and Companion Diagnostics
  • Disease Monitoring and Recurrence Detection

Early detection remains a key application area, while companion diagnostics and recurrence monitoring continue gaining importance in precision oncology.

By end user, the market serves:

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Centers
  • Academic & Research Institutes
  • Other End Users

Diagnostic laboratories and cancer centers continue expanding their molecular testing capabilities to support increasing demand for precision oncology services.

Market Trends

Several emerging trends are reshaping the prostate cancer diagnostics landscape:

  • Expansion of liquid biopsy technologies.
  • Increased use of genomic and molecular biomarker testing.
  • Growing adoption of AI-assisted imaging analysis.
  • Wider implementation of multiparametric MRI.
  • Development of minimally invasive diagnostic solutions.
  • Increasing integration of precision medicine into routine clinical workflows.
  • Expansion of digital pathology and automated diagnostic analytics.

Regional Insights

North America

North America remains the largest market due to advanced healthcare infrastructure, widespread screening programs, extensive precision medicine initiatives, and strong adoption of genomic diagnostics. The United States continues to lead innovation and commercialization in prostate cancer diagnostics.

Europe

Europe maintains a significant market share supported by strong healthcare systems, increasing use of mpMRI, growing precision oncology adoption, and expanding molecular testing capabilities.

Asia-Pacific

Asia-Pacific is expected to experience the fastest growth because of rising healthcare investments, growing awareness of cancer screening, increasing incidence of prostate cancer, and expanding access to advanced diagnostics. China, Japan, India, South Korea, and Australia are major contributors to regional growth.

Latin America and Middle East & Africa

These regions are gradually improving diagnostic access through healthcare modernization, infrastructure development, and increased investment in cancer care programs.

Competitive Landscape

The market is characterized by continuous innovation in molecular diagnostics, genomic testing, imaging technologies, and AI-enabled diagnostic platforms.

Key companies include:

  • Roche Diagnostics
  • Exact Sciences Corporation
  • Myriad Genetics
  • Bio-Techne Corporation
  • OPKO Health
  • MDxHealth
  • Thermo Fisher Scientific
  • QIAGEN
  • Danaher Corporation
  • Abbott Laboratories
  • Natera
  • Veracyte

Companies continue investing in liquid biopsy development, AI-powered diagnostics, genomic profiling, and companion diagnostic solutions to strengthen their competitive positions.

Future Outlook

The future of the prostate cancer diagnostics market will be increasingly centered on precision-driven diagnostic pathways. Liquid biopsy technologies, AI-enhanced imaging, molecular biomarkers, and genomic profiling are expected to become integral components of routine clinical practice. Healthcare systems are seeking to balance early detection with avoidance of unnecessary interventions, creating significant opportunities for innovative multi-modal diagnostic platforms.

Conclusion

The Global Prostate Cancer Diagnostics Market is expected to witness strong growth through 2035, supported by rising prostate cancer incidence, expanding precision oncology adoption, and continued advances in molecular diagnostics and imaging technologies. While challenges related to cost, reimbursement, and clinical validation remain, innovations in genomic testing, liquid biopsy, AI-enabled diagnostics, and advanced imaging are expected to create substantial opportunities for diagnostic developers, healthcare providers, researchers, and investors.

Key Benefits of this Report

  • Comprehensive assessment of the global prostate cancer diagnostics market.
  • Detailed evaluation of diagnostic technologies and emerging innovations.
  • Analysis of market dynamics, competitive strategies, and future opportunities.
  • Insights into precision oncology, liquid biopsy, AI, and molecular diagnostics.
  • Valuable resource for healthcare providers, diagnostic manufacturers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, competitive benchmarking, product development strategy, precision medicine planning, commercialization strategy, partnership evaluation, investment analysis, regulatory planning, and long-term business decision-making.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
  • Analysis by Product & Service, Diagnostic Technology, Application, End User, and Geography
  • Evaluation of PSA testing, PHI testing, PCA3 testing, genomic diagnostics, liquid biopsy, mpMRI, and tissue biopsy-based diagnostics
  • Assessment of screening, diagnosis, risk stratification, treatment selection, and recurrence monitoring
  • Competitive analysis of leading companies and emerging diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Prostate Cancer Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Disease Overview
  • 3.3 Industry Evolution
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast Analysis (2026-2035)
  • 3.7 Disease Burden and Unmet Diagnostic Needs
  • 3.8 Epidemiology and Prevalence Analysis
  • 3.9 Diagnosed Patient Population Analysis
  • 3.10 Screening and Testing Volume Analysis
  • 3.11 Patient Journey Analysis
  • 3.12 Prostate Cancer Screening Landscape
  • 3.13 Precision Oncology Diagnostics Overview

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies in Prostate Cancer Diagnostics
  • 6.2 Product Innovation Analysis
  • 6.3 Liquid Biopsy Advancements
  • 6.4 Molecular and Genomic Biomarker Developments
  • 6.5 Multiparametric Imaging Innovations
  • 6.6 Clinical Trial Analysis
  • 6.7 Pipeline Analysis
  • 6.8 AI Integration in Prostate Cancer Detection and Risk Stratification
  • 6.9 Digital Pathology and Diagnostic Workflow Integration
  • 6.10 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Prostate Cancer Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Technology Platform
  • 8.2 Analysis by Biomarker Type
  • 8.3 Analysis by Sample Type
  • 8.4 Analysis by Clinical Application
  • 8.5 Analysis by Testing Methodology
  • 8.6 Analysis by Screening versus Diagnostic Testing
  • 8.7 Analysis by End User

9. Prostate Cancer Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product & Service
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software & Diagnostic Analytics Solutions
    • 9.1.4 Diagnostic Testing Services
  • 9.2 By Diagnostic Technology
    • 9.2.1 Prostate-Specific Antigen (PSA) Testing
    • 9.2.2 Free PSA and PSA Derivative Testing
    • 9.2.3 Prostate Health Index (PHI) Testing
    • 9.2.4 PCA3 Testing
    • 9.2.5 Genomic and Molecular Diagnostics
    • 9.2.6 Liquid Biopsy Testing
    • 9.2.7 Multiparametric MRI (mpMRI)
    • 9.2.8 Tissue Biopsy-Based Diagnostics
  • 9.3 By Application
    • 9.3.1 Screening and Early Detection
    • 9.3.2 Disease Diagnosis and Confirmation
    • 9.3.3 Risk Stratification
    • 9.3.4 Treatment Selection and Companion Diagnostics
    • 9.3.5 Disease Monitoring and Recurrence Detection
  • 9.4 By End User
    • 9.4.1 Hospitals
    • 9.4.2 Diagnostic Laboratories
    • 9.4.3 Cancer Centers
    • 9.4.4 Academic & Research Institutes
    • 9.4.5 Other End Users

10. Prostate Cancer Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Prostate Cancer Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Netherlands
  • 11.9 China
  • 11.10 Japan
  • 11.11 South Korea
  • 11.12 Australia
  • 11.13 India
  • 11.14 Brazil
  • 11.15 Saudi Arabia

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
  • 13.2 Exact Sciences Corporation
  • 13.3 Myriad Genetics, Inc.
  • 13.4 Bio-Techne Corporation
  • 13.5 OPKO Health, Inc.
  • 13.6 MDxHealth SA
  • 13.7 Thermo Fisher Scientific Inc.
  • 13.8 QIAGEN N.V.
  • 13.9 Danaher Corporation
  • 13.10 Abbott Laboratories
  • 13.11 Siemens Healthineers AG
  • 13.12 Bio-Rad Laboratories, Inc.
  • 13.13 Veracyte, Inc.
  • 13.14 Genomic Health, Inc.
  • 13.15 Natera, Inc.

14. Prostate Cancer Diagnostics Market Commercial Forecast Analysis

  • 14.1 Forecast by Instruments
  • 14.2 Forecast by Reagents & Consumables
  • 14.3 Forecast by Software & Diagnostic Analytics Solutions
  • 14.4 Forecast by Diagnostic Testing Services
  • 14.5 Forecast by PSA-Based Testing
  • 14.6 Forecast by Genomic and Molecular Diagnostics
  • 14.7 Forecast by Multiparametric MRI Diagnostics
  • 14.8 Forecast by Liquid Biopsy Testing

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends